TY - JOUR AU - Ascione, Alessandro AU - Arenaccio, Claudia AU - Mallano, Alessandra AU - Flego, Michela AU - Gellini, Mara AU - Andreotti, Mauro AU - Fenwick, Craig AU - Pantaleo, Giuseppe AU - Vella, Stefano AU - Federico, Maurizio PY - 2019 DA - 2019/10/17 TI - Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion JO - BMC Biotechnology SP - 67 VL - 19 IS - 1 AB - Lymphocyte-activation gene (LAG)3 is a 498 aa transmembrane type I protein acting as an immune inhibitory receptor. It is expressed on activated lymphocytes, natural killer cells and plasmacytoid dendritic cells. In activated lymphocytes, LAG3 expression is involved in negative control of cell activation/proliferation to ensure modulation and control of immune responses. In view of its deregulated expression in tumor-infiltrating lymphocytes, LAG3, together with the additional immune checkpoint inhibitors CTLA4 and PD1, is considered a major target in order to reverse the immunosuppression typically mounting in oncologic diseases. Since many patients still fail to respond to current immune checkpoints-based therapies, the identification of new effective immune inhibitors is a priority in the ongoing fight against cancer. SN - 1472-6750 UR - https://doi.org/10.1186/s12896-019-0559-x DO - 10.1186/s12896-019-0559-x ID - Ascione2019 ER -